However, therapies that are capable of reactivating the expression of DNMT3L in human cells [including HDAC inhibitors and/or HMAs (10–13)] have already shown some promise in treating AML patients, and the observations noted here should be explored in future studies. Here, DNMT3L is linked to acute myeloid leukemia.